New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
07:54 EDTISISNEJM publishes study on loss-of-function mutations in APOC3
An article in the New England Journal of Medicine concluded, "Rare mutations that disrupt APOC3 function were associated with lower levels of plasma triglycerides and APOC3. Carriers of these mutations were found to have a reduced risk of coronary heart disease." Isis Pharmaceuticals is advancing an APOC3 antisense program into Phase 3, says Piper Jaffray. The firm believes the NEJM article further supports a role for the product beyond the pancreatitis-lowering benefit. Reference Link]:[http://www.nejm.org/doi/full/10.1056/NEJMoa1307095?query=featured_home]
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
07:37 EDTISISIsis Pharmaceuticals management to meet with Deutsche Bank
Subscribe for More Information
September 29, 2014
08:25 EDTISISIsis Pharmaceuticals management to meet with Deutsche Bank
Meetings to be held in Baltimore/Philadelphia on September 29 hosted by Deutsche Bank.
September 26, 2014
10:01 EDTISISOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:20 EDTISISIsis Pharmaceuticals assumed with a Market Perform at Leerink
Subscribe for More Information
September 25, 2014
08:59 EDTISISSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
September 22, 2014
15:14 EDTISISIsis Pharmaceuticals management to meet with JPMorgan
Meeting to be held in Los Angeles on September 22 hosted by JPMorgan.
September 17, 2014
07:29 EDTISISIsis Pharmaceuticals earns $4M from Achaogen for Phase 3 study of plazomicin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use